Chinese Academy of Sciences' Cash Holdings invested with its affiliate fund Guoke Ruihua to aid Shanghai Topgen's biotech development.
China-based precision medicine and diagnostics company Shanghai Topgen Pharmaceuticals has raised RMB120m ($17.1m) of series C funding from investors including Cash Holdings, an investment arm of Chinese Academy of Sciences (CAS), DealStreetAsia has reported.
Guoke Ruihua, an equity fund backed by CAS investment affiliate Shanghai Hantai Venture Capital, also took part in the series C round.
Shanghai Topgen is a precision medicine and in-vitro diagnostics supplier with 50 service outlets, five medical laboratories and a 1,500 square-metre drug…
